Improving outcomes in patients with advanced renal cell carcinoma.
The emergence of targeted therapies for advanced renal cell carcinoma has been a dramatic turning point in improving outcomes for the majority of patients with this disease. In study populations comprising primarily good- and intermediate-risk patients with clear cell renal cell carcinoma and prior nephrectomy, prolonged progression-free survival was demonstrated for three angiogenesis-targeted agents: sunitinib (compared with interferon [IFN]), bevacizumab plus IFN (vs IFN alone) and sorafenib (vs placebo in cytokine-refractory patients). As a first-line treatment for patients with multiple poor-risk factors, temsirolimus, which inhibits mTOR, has improved not only progression-free survival compared with IFN but, more importantly, overall survival. Further studies are needed to determine whether combinations and/or sequencing of these targeted agents can further improve outcomes.
Sosman
Jeffrey A
JA
Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232, USA. jeff.sosman@vanderbilt.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D018572:Disease-Free Survival; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors